CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 50 target
Drug / intervention
Abiraterone acetate +2 moredrug
Likely dose
Abiraterone acetate 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04736108
NCT04736108Phase 2Unknown
CompareCT.gov

A Single-center, Phase II Neoadjuvant Study of Abiraterone Acetate in the Treatment of Intraductal Carcinoma of the Prostate

West China Hospital·interventional·Posted Feb 3, 2021·Updated Feb 8, 2021

In Brief

A Phase 2 clinical trial evaluating Abiraterone acetate, Prednisolone, and 1 other intervention for Prostate Cancer. Targeting 50 participants across 1 site.

Detailed Summary

Neoadjuvant treatment before radical prostatectomy has been proven to provide benefits on peri-operation results, especially on reduction of tumor volume and minimization of biochemical recurrence. This study will evaluate the efficacy and safety of abiraterone acetate Plus androgen deprivation therapy（ADT）in high-risk localized prostate cancer with intraductal carcinoma of the prostate（IDC-P）.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
202120222023202420252026
First PostedFeb 3, 2021
Enrollment StartMay 1, 2021
Primary CompletionOct 1, 2022
Study CompletionDec 1, 2024
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago

Interventions

Abiraterone acetatedrug

1000 mg orally daily for 24 weeks before radical prostatectomy

Prednisolonedrug

5 mg oral low dose prednisone, once daily

Goserelindrug

10.8 mg goserelin hypodermic once per 12 weeks